FDA Issues Cancer Trial Guidance on Lab Values, Performance Status, Washout Periods and Concomitant Medications

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Issues Cancer Trial Guidance on Lab Values, Performance Status, Washout Periods and Concomitant Medications

J.W. Schomisch

April 26, 2024 at 02:29 PM EST

The FDA released three more draft guidances on cancer clinical trial eligibility criteria on April 25, bringing the total number of cancer trial eligibility criteria guidances to 13. The new guidances for sponsors, clinical investigators and institutional review boards deal with laboratory values, performance status and washout periods and concomitant medications. The labora... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Issues Cancer Trial Guidance on Lab Values, Performance Status, Washout Periods and Concomitant Medications

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT